Director/PDMR Shareholding

RNS Number : 7498T

Oxford Biomedica PLC

22 November 2013

 



For immediate release

22 November 2013

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 22 November 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 22 November that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired on 22 November 2013	Number of Ordinary Shares	% of total issued share capital
Nick Rogers	Chairman	2.4p	208,000	842,829	0.06%

The issued share capital of the Company is 1,416,149,005 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Investor Relations and Corporate Communications	Tel: [phone]
Media/Financial Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes to editors

1. About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

RDSBDBDBDXDBGXD